1 Nelson, N. P., Easterbrook, P. J. & McMahon, B. J. Epidemiology of Hepatitis B Virus Infection and Impact of Vaccination on Disease. Clin Liver Dis 20, 607-628, doi:10.1016/j.cld.2016.06.006 (2016).
2 Schweitzer, A., Horn, J., Mikolajczyk, R., Krause, G. & Ott, J. Estimations of worldwide prevalence of chronic hepatitis B virus infection: a systematic review of data published between 1965 and 2013. Lancet (London, England) 386, 1546-1555, doi:10.1016/s0140-6736(15)61412-x (2015).
3 The global, regional, and national burden of cirrhosis by cause in 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. The lancet. Gastroenterology & hepatology 5, 245-266, doi:10.1016/s2468-1253(19)30349-8 (2020).
4 Liu, J., Liang, W., Jing, W. & Liu, M. Countdown to 2030: eliminating hepatitis B disease, China. Bulletin of the World Health Organization 97, 230-238, doi:10.2471/blt.18.219469 (2019).
5 Papatheodoridis, G. et al. Discontinuation of oral antivirals in chronic hepatitis B: A systematic review. Hepatology (Baltimore, Md.) 63, 1481-1492, doi:10.1002/hep.28438 (2016).
6 Kim, T. et al. Hepatitis B virus DNA levels and overall survival in hepatitis B-related hepatocellular carcinoma patients with low-level viremia. Journal of gastroenterology and hepatology 34, 2028-2035, doi:10.1111/jgh.14750 (2019).
7 [The guidelines of prevention and treatment for chronic hepatitis B (2019 version)]. Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology 27, 938-961, doi:10.3760/cma.j.issn.1007-3418.2019.12.007 (2019).
8 Zhang, L. et al. Contemporary clinical research of traditional Chinese medicines for chronic hepatitis B in China: an analytical review. Hepatology (Baltimore, Md.) 51, 690-698, doi:10.1002/hep.23384 (2010).
9 Chen, Y. & Zhu, J. Anti-HBV effect of individual traditional Chinese herbal medicine in vitro and in vivo: an analytic review. J. Viral Hepat. 20, 445-452, doi:10.1111/jvh.12112 (2013).
10 Li, X. et al. Entecavir combining Chinese herbal medicine for HBeAg-positive chronic hepatitis B patients: a randomized, controlled trial. Hepatology international, doi:10.1007/s12072-020-10097-z (2020).
11 Chang, T. et al. Entecavir treatment for up to 5 years in patients with hepatitis B e antigen-positive chronic hepatitis B. Hepatology (Baltimore, Md.) 51, 422-430, doi:10.1002/hep.23327 (2010).
12 Yan, Y. et al. Down-regulation of cell membrane localized NTCP expression in proliferating hepatocytes prevents hepatitis B virus infection. Emerging microbes & infections 8, 879-894, doi:10.1080/22221751.2019.1625728 (2019).
13 Levrero, M. & Zucman-Rossi, J. Mechanisms of HBV-induced hepatocellular carcinoma. Journal of hepatology 64, S84-s101, doi:10.1016/j.jhep.2016.02.021 (2016).
14 Nguyen, M. H., Wong, G., Gane, E., Kao, J. H. & Dusheiko, G. Hepatitis B Virus: Advances in Prevention, Diagnosis, and Therapy. Clinical microbiology reviews 33, doi:10.1128/cmr.00046-19 (2020).
15 Wan, L. et al. Extracts of Qizhu decoction inhibit hepatitis and hepatocellular carcinoma in vitro and in C57BL/6 mice by suppressing NF-κB signaling. Scientific reports 9, 1415, doi:10.1038/s41598-018-38391-9 (2019).
16 Tajiri, H. et al. Effect of sho-saiko-to(xiao-chai-hu-tang) on HBeAg clearance in children with chronic hepatitis B virus infection and with sustained liver disease. The American journal of Chinese medicine 19, 121-129, doi:10.1142/s0192415x91000193 (1991).
17 Chang, J. S. et al. Sho-saiko-to (Xiao-Chai-Hu-Tang) and crude saikosaponins inhibit hepatitis B virus in a stable HBV-producing cell line. The American journal of Chinese medicine 35, 341-351, doi:10.1142/s0192415x07004862 (2007).
18 Lu, X. et al. Isorhamnetin: A hepatoprotective flavonoid inhibits apoptosis and autophagy via P38/PPAR-α pathway in mice. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie 103, 800-811, doi:10.1016/j.biopha.2018.04.016 (2018).
19 Lin, Y., Shen, C., Huang, Y. & Chang, Y. Homoflavonoids from Ophioglossum petiolatum. Journal of natural products 68, 381-384, doi:10.1021/np0401819 (2005).
20 Cai, F. et al. Yinchenhao decoction suppresses rat liver fibrosis involved in an apoptosis regulation mechanism based on network pharmacology and transcriptomic analysis. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie 114, 108863, doi:10.1016/j.biopha.2019.108863 (2019).
21 Wang, Z. et al. Cyclin B1/Cdk1 coordinates mitochondrial respiration for cell-cycle G2/M progression. Developmental cell 29, 217-232, doi:10.1016/j.devcel.2014.03.012 (2014).
22 Torres-Fernández, L. et al. The mRNA repressor TRIM71 cooperates with Nonsense-Mediated Decay factors to destabilize the mRNA of CDKN1A/p21. Nucleic acids research 47, 11861-11879, doi:10.1093/nar/gkz1057 (2019).
23 Tsang, F. et al. Aberrant Super-Enhancer Landscape in Human Hepatocellular Carcinoma. Hepatology (Baltimore, Md.) 69, 2502-2517, doi:10.1002/hep.30544 (2019).
24 Dasgupta, Y. et al. Normal ABL1 is a tumor suppressor and therapeutic target in human and mouse leukemias expressing oncogenic ABL1 kinases. Blood 127, 2131-2143, doi:10.1182/blood-2015-11-681171 (2016).
25 Topacio, B. et al. Cyclin D-Cdk4,6 Drives Cell-Cycle Progression via the Retinoblastoma Protein's C-Terminal Helix. Molecular cell 74, 758-770.e754, doi:10.1016/j.molcel.2019.03.020 (2019).
26 Hein, J. & Nilsson, J. Interphase APC/C-Cdc20 inhibition by cyclin A2-Cdk2 ensures efficient mitotic entry. Nature communications 7, 10975, doi:10.1038/ncomms10975 (2016).
27 Guo, J. & Guo, H. Metabolism and function of hepatitis B virus cccDNA: Implications for the development of cccDNA-targeting antiviral therapeutics. Antiviral research 122, 91-100, doi:10.1016/j.antiviral.2015.08.005 (2015).
28 Allweiss, L. et al. Proliferation of primary human hepatocytes and prevention of hepatitis B virus reinfection efficiently deplete nuclear cccDNA in vivo. Gut 67, 542-552, doi:10.1136/gutjnl-2016-312162 (2018).
29 Zheng, Y., Li, J., Johnson, D. & Ou, J. Regulation of hepatitis B virus replication by the ras-mitogen-activated protein kinase signaling pathway. Journal of virology 77, 7707-7712, doi:10.1128/jvi.77.14.7707-7712.2003 (2003).
30 Stöckl, L. et al. Integrity of c-Raf-1/MEK signal transduction cascade is essential for hepatitis B virus gene expression. Oncogene 22, 2604-2610, doi:10.1038/sj.onc.1206320 (2003).
31 Xia, L. et al. Upregulation of IL-23 expression in patients with chronic hepatitis B is mediated by the HBx/ERK/NF-κB pathway. Journal of immunology (Baltimore, Md. : 1950) 188, 753-764, doi:10.4049/jimmunol.1101652 (2012).
32 Fang, Z. et al. Polarization of Monocytic Myeloid-Derived Suppressor Cells by Hepatitis B Surface Antigen Is Mediated via ERK/IL-6/STAT3 Signaling Feedback and Restrains the Activation of T Cells in Chronic Hepatitis B Virus Infection. Journal of immunology (Baltimore, Md. : 1950) 195, 4873-4883, doi:10.4049/jimmunol.1501362 (2015).
33 Su, F. & Schneider, R. Hepatitis B virus HBx protein sensitizes cells to apoptotic killing by tumor necrosis factor alpha. Proceedings of the National Academy of Sciences of the United States of America 94, 8744-8749, doi:10.1073/pnas.94.16.8744 (1997).
34 Guo, L. & Liang, Y. Expression of PBMC apoptosis-related factors in patients with chronic hepatitis B and their relationships with clinical prognosis. Experimental and therapeutic medicine 14, 6007-6011, doi:10.3892/etm.2017.5299 (2017).
35 Ji, J., Zhang, Y. & Fan, Y. TIPE2 as a potential therapeutic target in chronic viral hepatitis. Expert opinion on therapeutic targets 23, 485-493, doi:10.1080/14728222.2019.1608948 (2019).
36 Kuo, C. et al. Apoptosis induced by hepatitis B virus X protein in a CCL13-HBx stable cell line. Oncology reports 28, 127-132, doi:10.3892/or.2012.1775 (2012).
37 Li, T., Yang, Y., Zhou, G. & Tu, Z. Immune suppression in chronic hepatitis B infection associated liver disease: A review. World journal of gastroenterology 25, 3527-3537, doi:10.3748/wjg.v25.i27.3527 (2019).
38 Ji, Y. et al. Serum from Chronic Hepatitis B Patients Promotes Growth and Proliferation via the IGF-II/IGF-IR/MEK/ERK Signaling Pathway in Hepatocellular Carcinoma Cells. Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology 47, 39-53, doi:10.1159/000489744 (2018).
39 Yoo, Y. et al. Hepatitis B virus X protein enhances transcriptional activity of hypoxia-inducible factor-1alpha through activation of mitogen-activated protein kinase pathway. The Journal of biological chemistry 278, 39076-39084, doi:10.1074/jbc.M305101200 (2003).
40 Moon, E. et al. Hepatitis B virus X protein induces angiogenesis by stabilizing hypoxia-inducible factor-1alpha. FASEB journal : official publication of the Federation of American Societies for Experimental Biology 18, 382-384, doi:10.1096/fj.03-0153fje (2004).
41 Chin, R. et al. Failure of lamivudine to reverse hepatitis B virus-associated changes in ERK, Akt and cell cycle regulatory proteins. Antiviral therapy 13, 221-230 (2008).
42 Ru, J. et al. TCMSP: a database of systems pharmacology for drug discovery from herbal medicines. J Cheminform 6, 13, doi:10.1186/1758-2946-6-13 (2014).
43 Walters, J. R. New advances in the molecular and cellular biology of the small intestine. Curr Opin Gastroenterol 18, 161-167, doi:10.1097/00001574-200203000-00002 (2002).
44 Xu, X. et al. A novel chemometric method for the prediction of human oral bioavailability. Int J Mol Sci 13, 6964-6982, doi:10.3390/ijms13066964 (2012).
45 Kim, S. et al. PubChem Substance and Compound databases. Nucleic Acids Res 44, D1202-1213, doi:10.1093/nar/gkv951 (2016).
46 O'Boyle, N. M. et al. Open Babel: An open chemical toolbox. J Cheminform 3, 33, doi:10.1186/1758-2946-3-33 (2011).
47 Daina, A., Michielin, O. & Zoete, V. SwissTargetPrediction: updated data and new features for efficient prediction of protein targets of small molecules. Nucleic Acids Res 47, W357-W364, doi:10.1093/nar/gkz382 (2019).
48 Szklarczyk, D. et al. STITCH 5: augmenting protein-chemical interaction networks with tissue and affinity data. Nucleic Acids Res 44, D380-384, doi:10.1093/nar/gkv1277 (2016).
49 Stelzer, G. et al. The GeneCards Suite: From Gene Data Mining to Disease Genome Sequence Analyses. Curr Protoc Bioinformatics 54, 1 30 31-31 30 33, doi:10.1002/cpbi.5 (2016).
50 Pinero, J. et al. The DisGeNET knowledge platform for disease genomics: 2019 update. Nucleic Acids Res 48, D845-D855, doi:10.1093/nar/gkz1021 (2020).
51 Brown, G. R. et al. Gene: a gene-centered information resource at NCBI. Nucleic Acids Res 43, D36-42, doi:10.1093/nar/gku1055 (2015).
52 UniProt, C. Reorganizing the protein space at the Universal Protein Resource (UniProt). Nucleic Acids Res 40, D71-75, doi:10.1093/nar/gkr981 (2012).
53 Szklarczyk, D. et al. STRING v11: protein-protein association networks with increased coverage, supporting functional discovery in genome-wide experimental datasets. Nucleic Acids Res 47, D607-D613, doi:10.1093/nar/gky1131 (2019).
54 Kohl, M., Wiese, S. & Warscheid, B. Cytoscape: software for visualization and analysis of biological networks. Methods Mol Biol 696, 291-303, doi:10.1007/978-1-60761-987-1_18 (2011).
55 Zhang, Y. et al. A systems biology-based investigation into the therapeutic effects of Gansui Banxia Tang on reversing the imbalanced network of hepatocellular carcinoma. Scientific reports 4, 4154, doi:10.1038/srep04154 (2014).
56 Xiao, Q., Wang, J., Peng, X., Wu, F. & Pan, Y. Identifying essential proteins from active PPI networks constructed with dynamic gene expression. BMC genomics, S1, doi:10.1186/1471-2164-16-s3-s1 (2015).
57 Saito, R. et al. A travel guide to Cytoscape plugins. Nat Methods 9, 1069-1076, doi:10.1038/nmeth.2212 (2012).
58 Ashburner, M. et al. Gene ontology: tool for the unification of biology. The Gene Ontology Consortium. Nat Genet 25, 25-29, doi:10.1038/75556 (2000).
59 Kanehisa, M., Sato, Y., Kawashima, M., Furumichi, M. & Tanabe, M. KEGG as a reference resource for gene and protein annotation. Nucleic Acids Res 44, D457-462, doi:10.1093/nar/gkv1070 (2016).
60 Dennis, G., Jr. et al. DAVID: Database for Annotation, Visualization, and Integrated Discovery. Genome Biol 4, P3 (2003).
61 Berman, H., Henrick, K. & Nakamura, H. Announcing the worldwide Protein Data Bank. Nat Struct Biol 10, 980, doi:10.1038/nsb1203-980 (2003).
62 Adams, P. D. et al. Announcing mandatory submission of PDBx/mmCIF format files for crystallographic depositions to the Protein Data Bank (PDB). Acta Crystallogr D Struct Biol 75, 451-454, doi:10.1107/S2059798319004522 (2019).
63 Trott, O. & Olson, A. AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. Journal of computational chemistry 31, 455-461, doi:10.1002/jcc.21334 (2010).
64 Yuan, S., Chan, H. C. S., Filipek, S. & Vogel, H. PyMOL and Inkscape Bridge the Data and the Data Visualization. Structure 24, 2041-2042, doi:10.1016/j.str.2016.11.012 (2016).
65 Barrett, T. et al. NCBI GEO: archive for functional genomics data sets--update. Nucleic acids research 41, D991-995, doi:10.1093/nar/gks1193 (2013).
66 Zhou, W. et al. Predictive model for inflammation grades of chronic hepatitis B: Large-scale analysis of clinical parameters and gene expressions. Liver Int 37, 1632-1641, doi:10.1111/liv.13427 (2017).